Insights and resources from the Molecule community

Track, trade, and explore the entire IP token ecosystem - onchain, in real time

It’s not about what gets cut today - it’s about the breakthroughs we may never see tomorrow.

Welcome to the latest building block of Molecule’s IP Protocol, Proof of Invention!

Molecule is excited to support pump.science with a BIO allocation for community growth initiatives. Through this BIO allocation, pump.science will explore ways to reward their early community members and create deeper connections within the DeSci eco

TL;DR pump.science & BIO are teaming up to power streamlined drug testing for BioDaos on Solana, starting with VitaDAO. Molecule is announcing the DeSci Ecosystem Grant w/ half its BIO token allocation Molecule has acquired $100k in $RIF and $100k i

In a recent episode of The DeSci Podcast, we welcomed Krister Kauppi, founder Rapamycin Longevity Lab, and Dr Mitchell Lee, CEO and co-founder at Ora Biomedical.

In light of the rapid technological advancements of our time, particularly in artificial intelligence and distributed ledger technology (DLT), the need to address the pain points of traditional science is becoming increasingly urgent.

Last year the AthenaDAO community chose to support Dr Mario Cordero’s work on ovarian aging. We’re excited to share the team’s promising data and announce a further fundraising round to move the project forward.

Let's face it, death is the final boss. It's the game over screen nobody wants to see. But what if you could develop your own infinite health cheat code? What if we could keep playing the game indefinitely? Let's play on pump.science.

Molecule's platform, Catalyst, empowers individuals to directly back scientific research projects that resonate with them. We are thrilled to announce our integration with Privy, a step that amplifies accessibility and usability for our community.

An important research milestone was reached — data showed ArtanBio’s AAV9-based gene therapy for aging has activity in vitro. This milestone demonstrates the power democratized funding can have towards advancing scientific progress. Read on for more.

Welcome to Catalyst, the DeSci funding machine that lets you decide the future of science.

With the beta launch of Catalyst, Molecule invites you to embark on an exciting journey with Catalyst Quests—a gamified adventure designed to onboard users into the DeSci movement.

Molecule, a leader in decentralized science (DeSci) and a pioneer in tokenized intellectual property (IP), is thrilled to announce its strategic partnership with CryoDAO.

We don’t know about you, but we’re still processing all the incredible ideas and information shared at this year's DeSci.Berlin!

Ringing in 2024, longevity stalwart VitaDAO has funded Dr. Michael Torres’ work to nullify a nonsense mutation that is implicated in a wide range of cancers and age-related diseases.

Sharing a mission of supporting early stage life sciences research and development, Molecule and Nucleate are joining forces to cultivate the next generation of bioentrepreneurs.

Dr Jack Scannell has been at the forefront of diagnosing the problems in biopharma research and development (R&D). As one of Molecule’s advisors, his work has inspired and informed much of Molecule’s positioning and goals.

In a compelling step forward, Sora Ventures has announced a significant investment in Molecule, marking a pivotal step towards integrating Decentralized Science (DeSci) in Asia.

We believe in a new era of scientific exploration powered by Decentralized Science (DeSci). This emerging concept, grounded in the principles of Meta- and Open-Science, leverages blockchain technology and decentralized networks to transform the lands

Moments that draw a community together act as an accelerant to progress. We recently hosted DeSci.Berlin 2023, facilitating essential conversations between key role players and encouraging knowledge to be dispensed liberally throughout the ecosystem.

In an exciting first step for ValleyDAO, Dr Rodrigo Ledesma Amaro has received funding to engineer oleaginous yeast to sustainably produce oils at an industrial scale, via an IP-NFT. Rodrigo’s work lights the way for future synthetic biology...

In a promising step for all women, AthenaDAO has committed $120K to Dr Mario Cordero’s work in ovarian aging. By funding overlooked research areas, AthenaDAO pushes the needle of women’s health forward, inviting all to contribute.

This guide explores raising money for research using tokenized Intellectual Property (IP) rights including IP Non-Fungible Tokens (IP-NFTs) and a new token type called IPTs mintable by IP-NFT holders. Note, this guide does not provide legal advice...

BioDAOs, such as VitaDAO, are using intellectual property non-fungible tokens (IP-NFTs) developed by Molecule to secure biotech IP and R&D data rights on Ethereum. Now BioDAOs are able to use their IP-NFTs to mint IPTs, fungible tokenized...

“Show me the incentive and I’ll show you the outcome” — Charlie Munger

On the 17th of August 2021, the first IP-NFT was traded, ushering in a new way of funding research. Since then, a total of six projects have been funded through the Molecule system.

HairDAO, a BioDAO that is currently a part of the bio.xyz accelerator, had their first IP-NFT transaction. For $75k, HairDAO will gain access to the initial data from Dr. Ralf Paus’ lab Cutaneon. Then, based on the results, HairDAO may opt to test...

On a recent episode of The DeSci Podcast, Vincent Weisser interviewed Vitalk Buterin, co-founder of the Ethereum Foundation, to talk about the state of decentralized science today and its prospects for the future which led to an in-depth analysis of the potential curveballs and unknowns.

The future of research is collaborative, digital, and highly autonomous. Patents today are not. We are building the intellectual property system that will help usher in this new era.

In 2021, our team at Molecule published the first implementation of intellectual property NFTs (IP-NFTs). A solution that wraps intellectual property rights such as patents, datasets, or contractual agreements inside a non-fungible token, enabling easy transfer and collective ownership over such assets. Together with VitaDAO, we managed to demonstrate that this new asset class can be a viable investment instrument for biotech research.

We are pleased to announce that Molecule’s IP-NFT funding framework will facilitate critical preclinical work in Dr. Amit Sharma’s laboratory at the SRF Research Center to eliminate the accumulation of senescent cells in age-related diseases.

This episode of the Desci Podcast explores decentralized science with Balaji Srinivasan. Balaji discusses the Network State, an era of decentralized academia, decentralized media, and decentralized science, and the difference between "science" and actual science.

Today we’re excited to announce Molecule’s IP-NFT funding paradigm has crossed the ocean to support age-related oral health research at the University of Washington in Seattle.

Ethan Perlstein, a well-known biotech founder and rare diseases advocate recently posted on Twitter that: "once you get a taste of decentralized biotech "it’s hard to go back to the centralized carnival of yore." It's as though he was talking about decentralized science (DeSci) itself. No event gave you this feeling better than the recent DeSci.Berlin gathering.

Today, we are excited to announce that we have raised $12.7M in seed funding. Led by Northpond Ventures with participation from Shine Capital, 1kx, Fifty Years, KdT Ventures, BACKED VC, Inflection VC, Chris Leiter, Balaji Srinivasan, Zee Prime Capital, The LAO, L1 Digital, Boom Capital, Compound VC, Koji Capital, Pillar VC, Seedclub Ventures, Speedinvest, Healthspan Capital, BoxGroup and many others - we are now one step closer to creating a more equitable future for researchers and patients.

We are delighted to share that the laboratory of Evandro Fang at the Akershus University Hospital and the University of Oslo became the third ever lab to fund their research project via Molecule’s IP-NFT framework - The discovery of novel mitophagy activators for Alzheimer´s disease and healthy longevity.

Paul Kohlhaas visited the Podcast of Andrew Steinwald, and spoke about his path into the pharmaceutical space and web3. He shares his experiences in biohacking, the pharma industry, the drug development process and how web3 could play a crucial role in making drug development more efficient, fair and transparent. This is achieved through BioDAOs an open source approach of pharmaceutical early stage research and leveraging the traits of NFTs through and a new standard, the IP-NFT. Molecule is a company that is virtualizing and decentralizing how drug development works. They do this by attaching data and IP rights to non-fungible tokens (NFT's) and then bringing the core IP into web3. This makes the intellectual property liquid, which is very hard to achieve in biotech today, and also enables price discovery around IP. Molecule has created a curation market where people can trade and discover therapeutics for drugs. Molecule has also started building biotech DAOs, which are research collectives that are comprised of patients, investors, and researchers in a specific therapeutic area. The mission is to democratize access to medicine by empowering researchers and patients to become co-owners of the IP and data associated with a new therapeutic. Paul describes how the company's IP-NFTs work to store data associated with a new therapeutic and how they can be used to fractionalize ownership of the IP. He also walks through the company's roadmap and explains how they plan to decentralize ownership of the data and IP associated with a new therapeutic. Paul discusses the origins of VitaDAO and IP-NFT, the process of setting up a DAO, and the long-term vision for a DAO-based ecosystem for pharmaceutical research and development.The grand vision for the projects is to develop a drug that is enabled and discovered through the process and reaches patients in a eight to ten year timeframe. He also discusses the potential for IP-NFTs to be used to fractionalize the ownership of IP and allow patients to contribute funding to research."

TL;DR: This week, the first university biomedical intellectual property (IP) and research project was funded as an NFT (non-fungible token), enabled by a pioneering innovation at Molecule. The IP-NFT enables new fundraising and collaboration strategies for researchers by combining legal and technical frameworks with NFT technology. Early-stage research can be financed without endless grant applications, creating a startup and raising VC or needing to file a patent.

Throughout the past 2 weeks VitaDAO Token Holders got to vote on the proposal “VDP-5 Scheibye-Knudsen Lab Funding” to fund longevity at the Scheibye-Knudsen Lab in Copenhagen. The voting passed with 2.1M token votes and 88% of votes supporting the proposition. With the proposal having been approved by the DAO members, the lab in Copenhagen will receive $250.000 for the first research phase of the project over a period of 12 months. After successful completion and review of Phase 1 by the DAO, another $250.000 for an additional 12 months of research could be handed out to the lab. As part of this deal, VitaDAO will fully own the intellectual property (IP) resulting from the research project. The first biopharma IP that will be owned and managed by a DAO. Ownership and access management to the IP will be handled via Molecule’s novel IPNFT framework. The infrastructure is utilizing Ethereum ERC721, Arweave and Nevermined.

Globally, early-stage biopharma research suffers from chronic underfunding, leading to discontinued research in the early stages of the pharma development cycle. This is happening so regularly that academia has coined the phase of research up until clinical trials the “Valley of Death”. Researchers struggle to acquire funding due to three distinct reasons:Lack of visibility and connection to relevant investors: Researchers struggle to connect and acquire funding from private investorsLegal complexity of IP deals: Deals such as licence agreements surrounding pre-patent and patent IP are complex and often need legal supportDifficulty of determining the value of early-stage biopharma assets: Both funders and researchers have trouble assessing the value of early-stage research.NFTs have created an unprecedented revolution in the creative space, rethinking copyright, royalties and IP. We believe it will also be instrumental in solving the above-stated problems. In this article, we are going to focus on the first technical implementation of a biopharma IPNFT. It builds on many concepts other influential thinkers in the Web3 space have conjured in the past. For example, if you are interested in how general IP can be combined with NFTs, have a look at Trent McConaghy 3 part series on building IP NFTs with ERC721.

Imagine a world where patients directly fund researchers developing the next therapeutic breakthrough they need. One where drug development is collaborative, open, and decentralized — an open bazaar anyone with the right intentions can join. A system that could radically increase the diversity of treatments, and lower costs and time to market.

In a few short weeks, we will be launching one of our flagship longevity projects with the University of Copenhagen’s Center for Healthy Aging. Here, our Chief Scientific Officer, Tyler Golato, discusses why Molecule is doubling down on longevity.

We are currently facing one of the largest healthcare crises in modern history — and it’s far from over. The hunt for cures and vaccines for COVID-19 is forcing scientists, governments and the public at large to rethink our current biopharma innovation models. They’re too slow, too expensive and risky. But there’s hope, because the current focus on vaccine and drug development is unparalleled in history and with it, scientists across the globe are quickly developing new collaborative ways of working together. I believe this crisis will catalyze a paradigm shift for new business models in pharma and biotech. Open markets in which drugs can be approved on much shorter time frames and smaller budgets, bringing treatments to patients at a fraction of the current cost. This shift is unavoidable. And it will be facilitated by new digital platforms that drive open science. We will break away from the traditional paradigm in drug discovery — to frictionless data sharing without the commercial constraints of intellectual property.

At the beginning of this year, the world was a different place, unrecognizable compared to the world we inhabit today. Over the past three months, we have witnessed the fabric of society change in profound ways previously unfathomable. We are living through, perhaps, the defining event of our lifetimes, and we will be judged by the history books based on how well we respond to the challenge at hand.

The pharmaceutical industry is facing a wide variety of challenges, but perhaps the most pressing is the ongoing innovation crisis. Drug discovery rates are declining, the price of bringing a drug to market is increasing, and ROI on R&D is expected to hit 0% in the next few years. Taken together, these factors have a direct impact on the number and types of therapeutics being brought to market. In light of the capital requirements being so high, drug discovery represents a special challenge for its actors, especially pharmaceutical and biotech companies and universities. Compounding these problems, industry and academia struggle with an unprecedented reproducibility crisis. Today, two innovative companies have joined forces to fight these trends.

We decided to create an integration between the Ocean Protocol and Molecule Catalyst, to enable DAO like management of research data produced from the projects funded via Molecule Catalyst, as well as monetize the research data to improve the value of the Molecule Catalyst markets for contributors.

Molecule Catalyst is a crowdfunding platform for Scientific research, and we are excited to introduce you to the first project that we will be hosting! The project is in partnership with Rotem Petranker and Thomas Anderson, directors at the University of Toronto Mississauga Psychedelic Studies Research Program (PSRP), the pioneering group leading the study that will take a look at the effects of microdosing psilocybin.

Launching your first product is no easy venture. Long hours, endless task lists and self-doubt are just a few elements involved in bringing your idea to life. The way you approach all these challenges is what will ultimately determine the success of your launch.